Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain independent and celebrate innovation across the UK life sciences industry and recognise achievements from emerging to late stage R&D companies, as well as life sciences investors.
A judging panel comprising a range of industry experts will decide the overall winner in each category, with the winning companies being announced at the OBN Awards Ceremony on Thursday 6th October at the Oxford Town Hall, UK.
Dr Barelle said about Elasmogen’s success: We are delighted that a young Scottish company has been recognised and shortlisted in this way. We have made excellent progress since our spin-out from the University of Aberdeen in February of this year. We are very much looking forward to attending the awards dinner and networking with industry colleagues.
John Harris, CEO of OBN, commented: “We are delighted with the great number of quality entries we received this year, in particular the Best Start-Up Biotech, Best Start-Up Medtech and the Best Implementation of Digital Healthcare Award categories. We are looking forward to celebrating some exciting new businesses and sharing some impressive achievements across the industry at our Awards in October.”
About Elasmogen’s technology
soloMER™ technology exploits the power of biologics (proteins) as drugs but in a small, 1/12 the size of an antibody, stable format that enables site specific delivery to and into cells and even through complex and challenging environments like the eye and gut. Unique to Elasmogen, and protected by a portfolio of granted patents, soloMERs are pre-disposed to generating potent neutralisers by binding in a unique way to drug targets. Their small size,
shows the potential for site-specific delivery to the eye but Elasmogen is also developing them, in collaboration with others, to penetrate and kill solid cancer tumours.
For further information please contact:
Dr Caroline Barelle – CEO
Elasmogen Limited (‘Elasmogen’ or the ‘Company’) is a private, UK-based biologics focused biopharmaceutical company. The Company has a late stage pre-clinical product portfolio of assets (soloMERs™) targeting large and important markets with significant unmet clinical needs.
The research and development portfolio includes ELN/21 and ELN/22 for the treatment of auto-inflammatory eye disease including a novel multi-active and sight-saving orphan therapy for refractory or corticosteroid resistant uveitis. In addition, the portfolio includes ELN/11 for the treatment of solid tumours – a potential blockbuster opportunity developed in partnership with Almac Discovery Ltd
The Company is also developing earlier stage compounds from its proprietary platforms for the site specific delivery of soloMERs to and importantly into cells.